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Solid tumor release into the circulation cell-free DNA (cfDNA) and circulating tumor
cells (CTCs) which represent promising biomarkers for cancer diagnosis. Circulating
tumor DNA may be studied in plasma from cancer patients by detecting tumor specific
alterations, such as genetic or epigenetic modifications. Ras association domain family 1
isoform A (RASSF1A) is a tumor suppressor gene silenced by promoter hypermethylation
in a variety of human cancers including melanoma. The aim of the present study was
to assess the diagnostic performance of a tumor-related methylated cfDNA marker in
melanoma patients and to compare this parameter with the presence of CTCs. RASSF1A
promoter methylation was quantified in cfDNA by qPCR in a consecutive series of 84
melanoma patients and 68 healthy controls. In a subset of 68 cases, the presence of
CTCs was assessed by a filtration method (Isolation by Size of Epithelial Tumor Cells,
ISET) as well as by an indirect method based on the detection of tyrosinase mRNA by
RT-qPCR. The distribution of RASSF1A methylated cfDNA was investigated in cases
and controls and the predictive capability of this parameter was assessed by means
of the area under the ROC curve (AUC). The percentage of cases with methylated
RASSF1A promoter in cfDNA was significantly higher in each class of melanoma patients
(in situ, invasive and metastatic) than in healthy subjects (Pearson chi-squared test,
p < 0.001). The concentration of RASSF1A methylated cfDNA in the subjects with a
detectable quantity of methylated alleles was significantly higher in melanoma patients
than in controls. The biomarker showed a good predictive capability (in terms of AUC) in
discriminating between melanoma patients and healthy controls. This epigenetic marker
associated to cfDNA did not show a significant correlation with the presence of CTCs,
but, when the two parameters are jointly considered, we obtain a higher sensitivity of the
detection of positive cases in invasive and metastatic melanomas. Our data suggest that
cell-free tumor DNA and CTCs represent two complementary aspects of the liquid biopsy
which may improve the diagnosis and the clinical management of melanoma patients.
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INTRODUCTION
Cell-free DNA (cfDNA) and circulating tumor cells (CTCs),
released into the bloodstream by solid tumors, are considered
real time liquid biopsies in cancer patients reflecting the disease
complexity at any stage of cancer progression. The liquid biopsy
represents a surrogate material for themolecular characterization
of solid cancers (Hodgson et al., 2010) which is particularly
valuable after the resection of primary tumor and in the
metastatic patients when multiple distinct tumor masses are
simultaneously present. In fact, in the advanced stages when the
tumor has acquired genetic, epigenetic and expression features
which may be very different from those of the primary tissue, the
liquid biopsy should represent a picture of the current molecular
state of the disease collecting cellular and molecular markers
from all the tumor sites in the organism.
CTCs and cfDNA are usually investigated separately and only
few studies assayed both CTCs and cfDNA focusing on the
correlation between the two parameters (Alix-Panabières et al.,
2012).
Total cfDNA concentration, higher in cancer patients than
healthy individuals (Fleischhacker and Schmidt, 2007), has been
proposed as a cancer marker, but it has shown limited sensitivity
and specificity (Jung et al., 2010).
On the other hand the identification tumor cfDNA, i.e., the
fraction of cfDNA deriving from the tumor, may help reaching
a higher diagnostic specificity. This task can be accomplished
by detecting tumor specific alterations, such as epigenetic
modifications among which aberrant DNA methylation in the
promoter region of tumor suppressor genes (Board et al., 2008)
plays a role in cancer progression and maintenance. Aberrant
cfDNA methylation has been described in most cancer types
and is being investigated for clinical applications (Warton and
Samimi, 2015). Methylation is a promising target for biomarker
development due to the stability of CpG island methylation
changes by comparison with the high variability of cancer
mutation profiles within a specific cancer (Warton and Samimi,
2015). In addition, methylated tumor cfDNA may be a more
sensitive marker for early-stage diseases as DNA methylation is
often an early event in carcinogenesis (Diaz and Bardelli, 2014).
RASSF1A (Ras association domain family 1 isoform A) is a
tumor suppressor gene, whose inactivation, mainly achieved by
promoter hypermethylation, is involved in the development of
many cancers (Donninger et al., 2007, 2015). So far the role
of RASSF1A methylation as a biomarker in cfDNA has been
investigated, mostly in combination with other parameters, in
a variety of tumors such as breast cancer (Papadopoulou et al.,
2006; Skvortsova et al., 2006; Agostini et al., 2012), prostate
cancer (Papadopoulou et al., 2006), lung cancer (Begum et al.,
2011; Ponomaryova et al., 2013), ovarian carcinoma (Bondurant
et al., 2011; Liggett et al., 2011; Zhang et al., 2013), gastric cancer
(Balgkouranidou et al., 2015), testicular germ cell cancer (Ellinger
et al., 2009), nasopharyngeal carcinoma (Wong et al., 2004),
renal cell carcinoma (de Martino et al., 2012), bladder cancer
(Hauser et al., 2013), and melanoma (Hoon et al., 2004; Koyanagi
et al., 2006; Salvianti et al., 2012). In this neoplasia RASSF1A
promoter methylation has a frequency of 55% (Spugnardi et al.,
2003). Methylation of RASSF1A increases significantly with
advancing clinical stage, suggesting that the inactivation of this
gene is associated with tumor progression (Tanemura et al.,
2009). RASSF1A promoter hypermethylation has been detected
in cfDNA from melanoma patients (Hoon et al., 2000; Marini
et al., 2006) in association to a worse response to therapy and
reduced overall survival (Mori et al., 2005; Koyanagi et al., 2006).
CTCs have been detected and characterized by means of
different methods in a variety of tumors, but their identification
as extremely rare cells in blood is challenging. In melanoma,
RT-qPCR is one of the most widely used methods for the indirect
detection of CTCs (Rodic et al., 2014), demonstrating high
sensitivity through the detection of marker RNA expression such
as tyrosinase mRNA coding for a melanocyte-specific enzyme.
Other methods used to investigate the presence of CTCs in
melanoma are able to maintain cell integrity separating CTCs on
the basis of their larger size with respect to blood cells (Rodic
et al., 2014). Studies on melanoma patients by different technical
approaches showed CTC detection rates ranging from 14 to 49%
in stage III and from 40 to 72% in stage IV melanomas (Khoja
et al., 2015).
The aim of the present paper was to investigate the role
of circulating methylated RASSF1A as a non-invasive marker
in melanoma patients and to compare RASSF1A methylation
status in cfDNA with the presence of CTCs identified by two
different methods (isolation of CTCs by size and quantification
of tyrosinase mRNA by RT-qPCR).
MATERIALS AND METHODS
Patients
Consecutive patients affected by primary and metastatic
cutaneous melanoma (n = 84) were enrolled at diagnosis at
the Department of Dermatological Sciences of the University of
Florence. The cohort included 37 females and 47 males with
median age of 62 years (range 23–94 years). Patients were affected
by in situ (n = 14, 9 males and 5 females, median age 60
years, range 39–80), invasive (n = 60, 33 males and 27 females,
median age 65 years, range 23–88), and metastatic melanoma
(n = 10, 5 males and 5 females, median age 50 years, range 28–
94). As a control population 68 healthy subjects were enrolled: 32
males and 36 females, median age 59 years (range 25–80 years).
The clinicopathological characteristics of melanoma cases are
reported in Table 1.
The research protocol was approved by the institutional
review board of the University of Florence and all the patients
signed an informed consent.
Sample Collection
Blood samples (5ml) were collected in EDTA tubes during
the dermatologic examination and before surgery, prior to any
treatment.
Plasma was separated within 3 h from blood draw by two
centrifugation steps at 4◦C for 10min at 1600 rcf and 14000
rcf, respectively. Plasma aliquots (505µl) were stored at −80◦C.
DNA was extracted from 500µl of plasma by the QIAamp DSP
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TABLE 1 | Clinicopathological characteristics of melanoma cases.
Parameter Number of cases Percent of cases
Total 84 100%
LOCATION
Head and Neck 6 7.1%
Limbs 24 28.6%
Chest 46 54.8%
Acral 5 6.0%
Genital 2 2.4%
Missing 1
THICKNESS
In situ 14 16.6%
≤1mm 39 46.4%
1–2mm 14 16.6%
2–4mm 9 10.7%
>4mm 3 3.6%
Missing 5
CLARK LEVEL
I 15 17.9%
II 14 16.7%
III 22 26.2%
IV 28 33.3%
Missing 5
ULCERATION
Absent 67 79.8%
Present 12 14.3%
Missing 5
SENTINEL LYMPH NODE
Negative 18 21.4%
Positive 3 3.6%
Not done 63 75.0%
STAGE OF DISEASE
0 13 15.5%
1 46 54.8%
2 7 8.3%
3 6 7.1%
4 12 14.3%
Virus Kit (QIAgen, Germany) according to the manufacturer’s
instructions. cfDNA extraction and subsequent molecular
analyses were performed consecutively during patients’ and
controls’ enrolment.
Quantification of the Methylated Form of
RASSF1A Promoter in cfDNA
The methylated form of RASSF1A promoter was quantified in
plasma by a qPCR assay according to an already described
protocol (Chan et al., 2006), after digestion of unmethylated
DNA by the methylation-sensitive enzyme Bsh1236I (Fermentas,
Canada) in a reaction volume of 25µl at 37◦C for 16 h.
Subsequently, 5µl of enzyme-treated DNA underwent a qPCR
assay for RASSF1A promoter, in a final volume of 25µl,
according to the protocol by Chan et al. (2006). As a control
for the enzymatic reaction we used a qPCR assay targeting an
unmethylated sequence of the ACTB promoter: the absence of
amplification signals for ACTB indicated a complete digestion
of the sample. A reference curve obtained by serial dilutions
of genomic DNA was used to quantify the methylated alleles.
Results were expressed as genomic equivalents (GE, each
corresponding to 6.6 pg DNA) per ml plasma (GE/ml pl).
Quantification of Total cfDNA
The quantity of the cfDNA circulating in plasma was evaluated by
a qPCR assay targeting the human gene APP (Amyloid Precursor
Protein, chr. 21q21.2, accessionNM_000484), as already reported
(Pinzani et al., 2010a). The cfDNA concentration was obtained
by interpolation on an external reference curve of genomic DNA
ranging from 10 to 105 pg/reaction. The results have been used to
calculate the percentage of tumor cfDNA applying the following
formula:
%tumor cfDNA = [RASSF1A methylated promoter
(GE/ml plasma)/APP (GE/ml plasma)]×100.
Detection of Circulating Tumor Cells
(CTCs)
The presence of CTCs was assessed in a subgroup of 68 patients
by the following two different methods:
Isolation by Size of Epithelial Tumor Cells (ISET)
Patients’ blood (10ml) was collected in EDTA tubes and
processed within 4 h. ISET was performed by means of an ISET
Device (Rarecells, France) as previously described (De Giorgi
et al., 2010). Briefly, the separation of CTCs is obtained by
filtration of blood through a membrane with 8µm pores after
lysis of red blood cells. Filters are stained with hematoxylin
and eosin. Samples with the presence of at least one CTC were
considered positive.
RT-qPCR for Tyrosinase mRNA
The presence of CTCs was determined by an indirect method
based on the detection by RT-qPCR of the mRNA for tyrosinase,
an enzyme which is involved in the biosysnthesis of the melanin,
thus specifically expressed by melanocytes and melanoma cells.
The protocol has been already reported (Pinzani et al.,
2010b). Briefly, total RNA from whole blood was isolated by the
PAXgene Blood RNA kit (PreAnalytiX, Switzerland), according
to the manufacturer’s instructions. RNA (500 ng) was reverse-
transcribed using Taqman Reverse Transcription Reagents
(Applied Biosystems, USA). To detect the tyrosinase transcript
a Taqman Gene Expression Assay (ID: Hs00165976_m1, Applied
Biosystems) was used. To calculate the expression of tyrosinase
mRNA in each sample, we referred to an external reference curve
generated by spiking a given number of cells of the melanoma
cell line SKMEL28 into the blood from healthy donors (range
4000–0.4 cells/ml blood). Based on a previous study on uveal
melanoma patients (Pinzani et al., 2010b) we established a cutoff
for tyrosinase expression of 0.08 SKMEL28 cell equivalents/ml
blood: all the samples showing a tyrosinase expression level
above this cut-off value were considered positive for the presence
of CTCs.
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Statistical Analysis
Statistical differences among qualitative results were assessed by
the Fisher’s exact test or Pearson chi-squared test. Differences in
quantities of RASSF1Amethylated cfDNA among distinct classes
of patients were assessed by the Mann–Whitney test. P-values
lower than 0.05 were considered significant.
We investigated the predictive capability (i.e., diagnostic
performance) of each marker by means of the area under the
ROC curve (AUC).
Statistical analysis was carried out using the IBM SPSS
Statistics software package, version 20.0 (IBM, NY, USA).
RESULTS
RASSF1A Promoter Methylation in cfDNA
The methylated form of the RASSF1A promoter was quantified
in cfDNA from melanoma patients and control subjects.
RASSF1A methylated alleles were detectable in 7/68 (10%)
healthy subjects and in 39/84 (46%) melanoma patients with a
significant association between the presence of methylated alleles
in cfDNA and the subjects’ category (Fisher’s exact test, p <
0.001).
The percentage of cases with methylated RASSF1A promoter
in cfDNA was higher respectively in in situ (8/14, 57%), invasive
(24/60, 40%), andmetastatic (7/10, 70%)melanoma patients than
in controls (Pearson chi-squared test, p < 0.001).
We did not find any significant relationship betweenRASSF1A
promoter methylation and the main clinicopathological
parameters such as Breslow thickness, Clark level, histotype, and
tumor site.
Quantitative data are reported in Table 2.
The concentration of RASSF1A methylated cfDNA in the
subjects with a detectable quantity of methylated alleles was
significantly higher in melanoma patients than in controls,
p = 0.001.
Figure 1A reports the median values and range of methylated
RASSF1A in cfDNA for subjects with detectable levels of
the marker. Control subjects show lower levels of circulating
methylated RASSF1A promoter than patients affected by in situ
(p = 0.004), invasive (p = 0.004) and metastatic melanoma
(p = 0.002). Metastatic patients have higher concentrations of
methylated RASSF1A alleles in plasma than patients with in situ
(p = 0.011) and invasive melanoma (p = 0.021).
The predictive capability (i.e., diagnostic performance) of
RASSF1A promoter methylation in plasma as a biomarker in
melanoma was investigated by means of the area under the ROC
curve. A good predictive capability was observed with an AUC of
0.905 (Figure 2).
We investigated also the diagnostic performance by
comparing healthy subjects with in situ and invasive melanomas,
obtaining an AUC of 0.946 (p = 0.004) and 0.863 (p = 0.004)
respectively (Figure 2). In addition we evaluated the prognostic
value of the marker by means of ROC curve analysis comparing
TABLE 2 | Quantitative data relative to RASSF1A promoter methylation.
Controls All melanoma patients (in situ
+invasive +metastatic)
In situ Invasive Metastatic
RASSF1A methylated cfDNA (GE/ml
pl) median (range)
2.80
(0.89-4.01)
12.49
(1.20-208.68)
8.85
(2.96-21.06)
12.99
(1.20-71.40)
32.85
(7.71-208.68)
Total cfDNA (GE/ml pl) 848
(150-7195)
2363
(135-31600)
2690
(882-7329)
2316
(135-31600)
2402
(689-19017)
Percentage of tumor cfDNA median
(Range)
0.21%
(0.02-1.64%)
0.46%
(0.02-11.55%)
0.37%
(0.07-2.39%)
0.43%
(0.02-11.55%)
0.80%
(0.12-8.84%)
FIGURE 1 | (A) Quantity of RASSF1A methylated cfDNA in different classes of melanoma patients and control subjects. (B) Percentage of tumor DNA circulating in
the plasma of different classes of melanoma patients and control subjects. Box plots represent the median values and interquartile range of RASSF1A methylated
cfDNA. mel, melanoma; inv, invasive; met, metastatic.
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FIGURE 2 | Receiver Operating Characteristic (ROC) curve of RASSF1Amethylated cfDNA in melanoma patients and control subjects. The table reports
the parameters of the ROC curve.
invasive and metastatic melanomas: the AUC was 0.792
(p = 0.021; Figure 2).
Percentage of Tumor DNA in Plasma
In order to establish the fraction of tumor DNA circulating in
plasma we calculated the percentage of RASSF1A methylated
DNA versus total cfDNA in samples with detectable levels of the
methylated marker. Quantitative data are reported in Table 2.
Healthy subjects have a significantly lower total cfDNA
quantity than patients affected by in situ (p < 0.001), invasive
(p < 0.001), and metastatic (p = 0.001) melanoma.
Patients affected by melanoma show a tendency to have a
higher percentage of tumor DNA than controls.
Median values tend to increase from healthy subjects to in situ,
invasive and metastatic melanomas but the differences among
classes are not statistically significant (Figure 1B).
ROC curve analysis revealed a worse diagnostic
performance for this relative parameter with respect
to the absolute quantification of tumor DNA itself
represented by methylated RASSF1A. The AUC, in fact,
is 0.670 ± 0.105, p = 0.155, (95% confidence interval:
0.464-0.877).
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TABLE 3 | Distribution of positive and negative cases for RASSF1A
methylation in cfDNA and for the presence of CTCs as assessed by
RT-qPCR for tyrosinase mRNA (Fisher’s exact test p = 0.061).
Methylated RASSF1A Total
neg pos
CTCs (by RT-qPCR
for tyrosinase mRNA)
neg 30 20 50
pos 6 12 18
Total 36 32 68
TABLE 4 | Distribution of positive and negative cases for RASSF1A
methylation in cfDNA and for the presence of CTCs as assessed by ISET
(Fisher’s exact test p = 0.790).
Methylated RASSF1A Total
neg pos
CTCs (by ISET) neg 27 23 50
pos 9 9 18
Total 36 32 68
No significant correlation was found between methylated
RASSF1A levels in cfDNA and total cfDNA concentration
(Spearman’s correlation coefficient ρ = −0.128, p = 0.398).
Comparison Between cfDNA and CTCs
With the aim of defining the relationship between CTCs and
tumor cell-free DNA, we assessed the presence CTCs in the
blood of 68/152 subjects of our case study for whom we could
take an additional blood draw. The 68 cases with CTC analyzed
were distributed as follows: 12 in situ melanomas, 48 invasive
melanomas, and 8 metastatic melanomas.
CTCs were detected by an indirect method based on a RT-
qPCR assay for tyrosinase mRNA as well as a filtration-based
method (ISET).
We found no significant relationship between the presence
of CTCs assessed by either method and cfDNA methylated in
RASSF1A by the Fisher’s exact test (Tables 3, 4, p = 0.061 and
p = 0.790, respectively). Analogously, by performing the same
analysis in the three different patients’ categories of our case study
we found no significant association.
On the contrary, the two methods for detecting CTCs showed
a significant association between each other by the Fisher’s exact
test (p = 0.013, Table 5). On the other hand, the association was
lost when analyzed within patients’ categories.
By combining the determination of the circulating methylated
RASSF1Amarker with the detection of CTCs with either method,
we increased the sensitivity of the detection of positive cases in
invasive and metastatic melanomas (Table 6).
Correlation on the basis of quantitative data between
RASSF1A and CTC with either method did not provide any
significant result (Spearman’s correlation, ρ = 0.245, p = 0.177
for ISET and ρ = 0.336, p = 0.060 for RT-qPCR).
TABLE 5 | Distribution of positive and negative cases for the presence of
CTCs as assessed by ISET and RT-qPCR for tyrosinase mRNA (Fisher’s
exact test p = 0.013).
CTCs (by RT-qPCR for tyrosinase mRNA Total
neg pos
CTCs (by ISET) neg 41 9 50
pos 9 9 18
Total 50 18 68
TABLE 6 | Number of positive cases per class of melanoma patients
obtained by assessing RASSF1Amethylated cfDNA, the presence of CTCs
by either method, and by combining the determination of the circulating
methylated RASSF1A marker with the detection of CTCs.
Number of positive cases/total (%)
Class Methylated
RASSF1A
CTC Methylated RASSF1A
OR CTC
In situ 7/12 (58%) 3/12 (25%) 7/12 (58%)
Invasive 20/48 (42%) 18/48 (37%) 29/48 (60%)
Metastatic 5/8 (62%) 6/8 (75%) 8/8 (100%)
DISCUSSION
The analysis of cfDNA may have the potential to complement
or replace the existing cancer tissue and blood biomarkers
in the future (Schwarzenbach et al., 2011). In order to reach
this goal, specific and sensitive analytical procedures must be
developed and optimized to target circulating molecules showing
differences between patients and healthy subjects.
In this study, we investigated the diagnostic performance of
RASSF1A promoter methylation in cfDNA as a non-invasive
marker of tumor DNA in melanoma patients. We focused our
attention on the methylated form of the marker since it is
supposed to represent the fraction of circulating DNA deriving
from the tumor by any of the hypothesized mechanisms of
necrosis, apoptosis and active release (Jung et al., 2010).
We considered patients at different stages of melanoma
disease in order to test the reliability of the epigenetic marker
under study independently from the stage of the tumor.
Since the possible sources of CTCs and cfDNA in patients
with different clinicopathological characteristics are still non-
completely disclosed, we chose to jointly analyze the whole case
study in order to test the reliability of the epigeneticmarker under
study, independently from the stage of the tumor.
Notwithstanding the limited number of cases with a detectable
level of methylated RASSF1A, especially among healthy subjects,
our results demonstrated a good capability of this marker in
distinguishing between melanoma patients and healthy control
subjects, as evidenced by the ROC curve analysis.
The absolute levels of the epigenetic marker are significantly
higher in melanoma compared to controls and increases during
tumor progression (from in situ to invasive and metastatic
disease). In order to evidence both the diagnostic and prognostic
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potential of the investigated marker, we chose to compare
invasive with in situ and metastatic melanomas even though the
last two patients’ categories are less represented in our cohort.
When expressing the results as a percentage of the total
amount of cfDNA present in the sample (% tumor DNA) the lack
of statistical significance indicates that the tumor DNA values are
relevant independently from the cfDNA deriving from different
sources within the organism, highlighting that the development
of assays that specifically recognize the DNA of tumor origin is a
major requirement when analyzing the liquid biopsy.
Moreover, we correlated data on methylated cfDNA with
the simultaneous presence of CTCs in the same blood draw of
our cohort of subjects in order to investigate the relationship
between these two aspects of the liquid biopsy. We found no
significant correlation among the two biomarkers analogously
to what recently reported in a study on breast cancer patients
(Madic et al., 2015).
Some researchers investigated this topic finding an overall
agreement between the two parameters (Koyanagi et al., 2006;
Schwarzenbach et al., 2009; Van der Auwera et al., 2009;
Matuschek et al., 2010; Chimonidou et al., 2013), while others
reported that cfDNA is more frequently detected than CTCs
in cancer patients (Bidard et al., 2014; Madic et al., 2015).
Two studies pointed out a higher sensitivity in mutation
detection for tumor cfDNA than CTCs (Punnoose et al., 2012;
Freidin et al., 2015). These discrepant results can be partially
due to the different methodological approaches used by the
researchers. In fact, when comparing these two biomarkers
it must be also taken into account that CTC detection is
a challenging objective to achieve in the laboratory for the
lack of a unique standardized procedure to refer to and
for the intrinsic difficulties of the methods for the isolation
of these cells which represent a minority of the nucleated
blood cells. On the other hand, also cfDNA evaluation is
technically challenging due to the low concentration of cfDNA
and to the high levels of interfering, non-tumor-specific DNA
fragments present in plasma. Moreover, the origin of the
cfDNA has not been clarified yet and some authors suggest
that tumor cfDNA derives, at least in part, from CTC lysis
in the circulation, but nonetheless the two parameters cannot
be considered completely overlapping. The most commonly
accepted opinion is that CTCs and cfDNA represent two
complementary aspect of the liquid biopsy and thus should
both be considered to reach a non-invasive approach to cancer
management.
In our experience, by the comparison of RASSF1Amethylated
cfDNA with CTCs, it was apparent that they represent two
independent biomarkers that could be jointly measured and
integrated in the liquid biopsy. The 100% specificity in the
detection of metastatic patients was reached by combining the
two parameters indicating that both circulating markers should
be employed in order to enhance the possibility of disease
monitoring in a higher percentage of patients.
The univariate analysis performed so far allowed us to assess
the performance of methylated RASSF1A as a marker of tumor-
related cell-free DNA in melanoma for diagnostic purposes being
able to discriminate the in situ and invasive melanomas from
controls and as an indicator of patients prognosis, as assessed
by the good discriminative power of the ROC curve including
invasive and metastatic patients.
Further studies are needed to define an algorithm integrating
quantitative data related to cfDNA and CTCs.
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